Key result
Lifelong consumption of ginsenoside Rg1 did not significantly affect longevity (651 vs 706 days, p=0.77) or tumor incidence (12% vs 19%, p=0.24) in rats, but maintained spontaneous mobility.
Why the study?
Effects of the major ginsenoside Rg1 on mammalian longevity and physical vitality are rarely reported.
Does lifelong oral supplementation of ginsenoside Rg1 improve longevity, tumor incidence, and physical vitality in Wistar rats?
RCT (n=138)
randomized
Does lifelong oral supplementation of ginsenoside Rg1 improve longevity, tumor incidence, and physical vitality in Wistar rats?
Lifelong consumption of ginsenoside Rg1 in rats delays age-dependent decline in physical vitality and modulates inflammation, but does not significantly affect longevity or tumorigenesis.
Answers are grounded in this paper and cite their sources.
Animal data show no longevity effect; leaves open ginsenoside Rg1 effects on age-related physical decline for translational research.
Background Effects of the major ginsenoside Rg1 on mammalian longevity and physical vitality are rarely reported. Purpose To examine longevity, tumor, and spontaneous locomotor activity in rats consuming Rg1. Methods A total of 138 Wistar rats were randomized into 2 groups: control (N = 69) and Rg1 (N = 69). Rg1 (0.1 mg/kg per day) were orally supplemented from 6 months of age until natural death. Spontaneous mobility was measured by video-tracking together with body composition (dual energy x-ray absorptiometry) and inflammation markers at 5, 14, 21, and 28 months of age. Results No significant differences in longevity (control: 706 days; Rg1: 651 days, p = 0.77) and tumor incidence (control: 19%; Rg1: 12%, p = 0.24) were observed between the two groups. Movement distance in the control group declined significantly by ∼60% at 21 months of age, together with decreased TNF-α ( p = 0.01) and increased IL-10 ( p = 0.02). However, the movement distance in the Rg1 group was maintained ∼50% above the control groups ( p = 0.01) at 21 months of age with greater magnitudes of TNF-α decreases and IL-10 increases. Glucose, insulin, and body composition (bone, muscle and fat percentages) were similar for both groups during the entire observation period. Conclusion The results of the study suggest a delay age-dependent decline in physical vitality during late life by lifelong Rg1 consumption. This improvement is associated with inflammatory modulation. Significant effects of Rg1 on longevity and tumorigenesis were not observed.
No takes yet. Share an insight, caveat, or question.
Hsieh et al. (2021) conducted an RCT in Healthy Wistar rats (n=138). ginsenoside Rg1 vs. control was evaluated on longevity (p=0.77). Lifelong consumption of ginsenoside Rg1 did not significantly affect longevity (651 vs 706 days, p=0.77) or tumor incidence (12% vs 19%, p=0.24) in rats, but maintained spontaneous mobility.
Synapse has enriched 10 related papers. Consider them for comparative context: